Market Data
News
Tools
Markets
Discover
Subscribe Login/Register
FTSE 100
7,627.20
(
0.74%
)
Dow Jones
33,093.34
(
1.0%
)
Gold vs US Dollar
1,946.67
(
0.0%
)
Brent Oil
77.22
(
0.0%
)
Bitcoin
26,855.53
(
-0.05%
)
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Hemogenyx Pharmaceuticals Plc (HEMO)

  7. Hemogenyx Pharmaceuticals Plc (HEMO) Share Price

HEMO

Hemogenyx Pharmaceuticals Plc

2.05
-0.025 (-1.2%)
Upgrade to Real-Time
Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx Pharmaceuticals Plc LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
Upgrade Icon
  -0.025 -1.2% 2.05 6,395,810 08:44:30
Bid Price Offer Price High Price Low Price Open Price
2.00 2.10 2.075 2.05 2.075
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Finance Services 0.00 -3.98 - - 23.41
Last Trade Time Trade Type Trade Size Trade Price Currency
16:25:18 O 15,000 2.0361 GBX
Related Shares
Astrazeneca (AZN), Gsk (GSK), Fusion Antibodies (FAB), Yourgene Health (YGEN)

Hemogenyx Pharmaceuticals (HEMO) Latest News

Hemogenyx Pharmaceuticals News

Date Time Source Headline
09/5/202315:16ALNCNewsIN BRIEF: Hemogenyx submits FDA application for Hemo-Car-T treatment
09/5/202307:00UKREGHemogenyx Pharmaceuticals PLC Submission of IND for HEMO-CAR-T
28/4/202315:35ALNCNewsEARNINGS SUMMARY: DP Aircraft profit swing, Chesterfield loss widens
28/4/202310:05UKREGHemogenyx Pharmaceuticals PLC Equity Incentive Pool Increase and Option..
28/4/202307:00UKREGHemogenyx Pharmaceuticals PLC Final Results for the Year Ended 31 December..
23/3/202320:32ALNCNewsTRADING UPDATES: Fragrant Prosperity to buy Hi 55, Oscillate talks end
23/3/202313:32RNSNONHemogenyx Pharmaceuticals PLC HEMO-CAR-T Analytical Release Tests Completed
28/2/202307:00UKREGHemogenyx Pharmaceuticals PLC Total Voting Rights
07/2/202314:30UKREGHemogenyx Pharmaceuticals PLC Admission of Shares to Official List
26/1/202310:45ALNCNewsHemogenyx raises GBP4 million in share placing for Hemo-CAR-T product

Hemogenyx Pharmaceuticals (HEMO) Discussions and Chat

Hemogenyx Pharmaceuticals Forums and Chat

Date Time Title Posts
25/5/202313:42HEMO8,666
13/1/202314:28Hemogenyx- Official Thread 373
14/3/202216:13HEMO 2020/21 Discussion MODERATED3,217
11/1/202212:16Hemogenyx - 2021 Entry to clinical status288
09/6/202115:22Hemogemyx - nomoderated25

Add a New Thread

Hemogenyx Pharmaceuticals (HEMO) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Hemogenyx Pharmaceuticals (HEMO) Top Chat Posts

Top Posts
Posted at 04/4/2023 13:20 by bobdown2
Have filtered the repetitious ones. Same format here as the lse.
This is easily checked. The share price was marked up this morning. It is now nearly knocking on the offer. I think we could see the spread widen upwards after a few buys. The placings mean you cannot do comparisons but hemo reached around 6 pence on the recent rise. News of more importance could put the share price at 5 pence.
I topped up last week. Sub 2.00. The gains from these levels could be substantial. Watch the trades and not the idiots.
Read Full Thread
Follow
Reply
Posted at 31/3/2023 14:38 by bobdown2
It's very strange that there are so many people that want shares to go down and post derogatory posts. I Try to spot share price movement on the upside.
Read Full Thread
Follow
Reply
Posted at 31/3/2023 12:54 by bobdown2
Where does buying volume originate from. Who knows? But it might be from those that have more knowledge about what the company is doing than other investors. Posts for the downside? Are they as important as the extra volume that is required to move a share price up. I think not. A poster first thing today has already seen his pessimistic post start to turn wrong. In my view! If a share has delayed news and the share price picks up on increased volume then it is time to take notice. Especially when the products could prove to be very important.
Read Full Thread
Follow
Reply
Posted at 31/3/2023 04:07 by badger60
Oh well....still no IND and MadVlad has recently scammed investors out of 4 Mio quid at 2.5pps.....as the share price languishes below 2p. Cash burn must be much higher now with the new facility and additional staff, so shareholders can expect the next fundraiser,,,if he can get one away....sooner than usual. Doubtless the hard core mugs will still go for it,as MadVlad will post some Twitter twaddle, all of which to date has come to nought.If the next fundraiser happens it'll be lucky to come at much more than 1pps, and considering the 1.4bn shares already issued.To raise any meaningful amount the dilution will be significant, and the share certs wiki be cheaper than Russian bog roll.....
Read Full Thread
Follow
Reply
Posted at 23/3/2023 13:49 by ashleyjv
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of a full set of analytical tests required to verify the quality of the cells manufactured during three Process Qualification ("PQ") runs of the end-to-end process for HEMO-CAR-T production. Each PQ run is an end-to-end process of the manufacture of HEMO-CAR-T cells. The PQ runs were carried out in the Company's current Good Manufacturing Practice ("cGMP") compliant clean rooms. They were followed by analytical release tests that were conducted both by the Company and a third party to ensure that manufactured HEMO-CAR-T cells comply with a set of required quality attributes. Among these attributes are viability, potency and sterility of the manufactured HEMO-CAR-T cells.

The completion of the full set of analytical tests of all PQ runs is the last manufacturing requirement that is necessary for the submission of an Investigational New Drug ("IND") application to the US Food and Drug Administration ("FDA"), which is now in the course of preparation. The IND is needed to obtain authorization from the FDA to commence Phase I clinical trials of HEMO-CAR-T. All PQ runs as well as analytical tests data will be compiled for inclusion in the IND submission pack.
Read Full Thread
Follow
Reply
Posted at 13/2/2023 15:53 by chimpychops81
Badger
Its been a while
Still slagging HEMO off I see, even going strong after its started its move north. You do know that getting the IND app to FDA for CAR T will be monumental for the share price dont you? Going clinical? The actual route to commerciality.

Some might say if HEMO hadnt raised on this share price rise then they would have been badly run. Companies always raise after big share price runs. Its pretty much standard. Dilution is inevitable yet you talk about it as if its just some bad option Vlad has picked? They have plenty of cash now, cash is king as they say. Vlad is the tightest man alive and has run HEMO on a shoe string budget for years. Cash burn continues to be a low risk area for HEMO. When companies raise you need to know where the money is going. This is not some lifestyle company needing cash for wages and to keep the lights on, money is being ear marked for project work across the HEMO portfolio.

You are still droning on about not earning any income yet! You are correct, pretty everyone understands whats going on in the department. But HEMO are getting a lot closer to making some dosh now, a lot closer. Moving clinical, getting the nod from FDA. The fact that the drug sounds good/effective/safe and have all the correct procedures in place to test it properly reflects exceptionally well on HEMO. External consultants utilised to check the app prior to submission, further verifying the quality of HEMOs work. Exciting times!

Why do you still post on here? Im just interested? It sounds very personal for you! You NEED to see HEMO fail. Im honestly worried for your mental health now because they are on the cusp of becoming a clinical junior pharma. Its a real milestone, even you have to admit that.
Read Full Thread
Follow
Reply
Posted at 17/1/2023 00:37 by badger60
Good luck to those who bought in the 1's etc. , got it right and are in the money. Despite my doubts about MadVlad's ability to run a company......the share price doesn't lie, and it's good to see others making a few bob. Just beware of a fundraiser.......if MadVlad is stepping up expenditure with work, hiring and new premises, then the 5 Mio that they had last June won't last too long.Looking at current share price levels....he may be looking a 3-3.5p new issue price....and raising 10- 15 Mio quid, imo.
Read Full Thread
Follow
Reply
Posted at 18/11/2022 16:37 by ashleyjv
HEMO-CAR-T Process Development Runs Completed

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its second and final Process Development ("PD") run of the end-to-end process for the manufacture of HEMO-CAR-T cells. The process was carried out in the Company's current Good Manufacturing Practice ("cGMP") compliant clean rooms.

This is another step for the Company in its preparation of the Investigational New Drug ("IND") application to the US Food and Drug Administration ("FDA") required to authorise commencement of Phase I clinical trials of HEMO-CAR-T. The Company's amazing team of scientists is now moving toward engineering runs (Process Qualification) of HEMO-CAR-T cell production.
Read Full Thread
Follow
Reply
Posted at 10/8/2022 07:10 by sweepie2
("Hemogenyx Pharmaceuticals" or the "Company")



Appointment of Medical Director

One of America's Top Bone Marrow Transplant and Oncology Doctors Joins Hemogenyx Pharmaceuticals as Medical Director



Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces the appointment of Dr Koen van Besien as Medical Director.

Dr van Besien is Chief of the Division of Hematology and head of the Wesley Center for Immunotherapy at University Hospitals Seidman Cancer Center, a cellular therapy facility that generates CAR-T and CAR-NK among other cell therapies. He has been associated with the Company as a scientific adviser from its founding and, now that the Company is moving close to clinical trials, we are delighted that he is able to step up to a position where he will be actively engaged in refining the protocol for the trials and its implementation.

Dr van Besien is Editor in Chief of the Journal of Leukemia and Lymphoma and a member of the editorial boards of several journals including Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation. He has published more than 300 peer-reviewed papers.

Most recently, Dr van Besien was Director of the Stem Cell Transplant Program at New York Presbyterian Hospital and a professor of Medicine at Weill Cornell Medical College.

Dr van Besien graduated from Medical School at the University of Leuven, Belgium and holds a PhD from Maastricht University in the Netherlands. He completed his hematology/oncology fellowship at Indiana University and in Bruges, Belgium. Dr van Besien has served on the faculty of The University of Texas MD Anderson Cancer Center in Houston. He also directed transplant programs at the University of Illinois for four years and at the University of Chicago for a decade.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:

"We are excited to welcome Dr Koen van Besien as Medical Director. Koen's rich experience and deep insight into the cutting-edge treatments of patients suffering from blood cancers will undoubtedly help to accelerate Hemogenyx Pharmaceuticals' product candidates, and specifically in the short term the transition into the clinic of HEMO-CAR-T, our lead product candidate."

Dr Koen Van Besien, Medical Director of Hemogenyx Pharmaceuticals, commented:

"I have been privileged to work with Hemogenyx since its founding. It is great to see their research efforts come to fruition and I am committed to helping bring their first product to the clinic."



Enquiries:
Read Full Thread
Follow
Reply
Posted at 24/1/2022 17:01 by justhereforhemo
Bager are you going to apologise for the part you played in trading/shorting the share price down? I dont think so, you won and like you said you made alot of money doing so, but yet your still desperate to also be seen as the hero. Lets say everyone had thought "Wow! Badger is right lets everyone sell and save our money!" How exactly would that have played out? How many people could have sold before the MMs just put a break on selling and gaped down the SP? I think you genuinely want people to believe your not a bad guy but you cannot see that the only way for people to have not lost money was for the share price to have been supported and boosted 12 months ago before the CLNs were ever drawn down.
Go back a year when you and Purple were attacking Hemo with vigour, the mCap was what? 60mil? 12 mil draw down would have been 20%, there was something like 400mil shares. If you and others had gotten behind the company, supported Vlad, spread the word, then any conversions which were very slow and non damaging at the start would have been at 10+p and not 4/5/6p. Hemo would have gotten their money, investors would not have been diluted into the ground and we would not be having this discussion right now.
The ONLY way for everyone to win was for the share price to go up, your forcing the share price down was never ever going to benefit anyone other than you and mint.

Perhaps someone else would have stepped in and started tanking the SP, perhaps Mint would have been alot more aggressive at higher SP? We dont know and will never know, and its irrelevant, you won, you made alot of money and you cost lots of people including myself ALOT of money. But unlike you I am willing to move on because its the past and has zero impact on the fact that the CLNs are gone and hemo are within touching distance of clinical trials. HAve a good evening
Read Full Thread
Follow
Reply
Hemogenyx Pharmaceuticals share price data is direct from the London Stock Exchange
Your Recent History
LSE
HEMO
Hemogenyx ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: D: 20230528 00:09:04